Study the Effects of CYP2C Polymorphisms on the Pharmacokinetics and Pharmacodynamics of Glipizide

Chinese Academy of Sciences

Status: Completed

Conditions: Healthy

Study type: Observational

Funder types: Other

Identifiers

NCT00806013

SIMM-080601

Details and patient eligibility

About

The aims of this study were to investigate the effects of CYP2C9 and CYP2C19 polymorphisms on the pharmacokinetics and pharmacodynamics of glipizide in healthy Chinese subjects.

Full description

Compared with CYP2C19, CYP2C9 polymorphism appears to have a dominant role in glipizide pharmacokinetics and pharmacodynamics in vivo. This indicated that dose adjustment based on CYP2C9 genotype may improve antidiabetic treatment.

Enrollment: 36 patients

Sex: Male

Ages: 21 to 27 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• nonsmokers and in good health

Exclusion criteria

• family history of diabetes mellitus
• taking any drug, alcohol, foods containing caffeine, or grapefruits and juice before study

Trial design

36 participants in 3 patient groups

1

Description:

CYP2C9\*1/\*1 and CYP2C19\*1/\*1 alleles carrier

2

Description:

CYP2C19 PMs (CYP2C19\*2/\*2, CYP2C19\*2/\*3 or CYP2C19\*3/\*3)

3

Description:

CYP2C9\*1/\*3 and CYP2C19\*1/\*1 alleles carrier